SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines. (PubMed, Hum Vaccin Immunother) - Jan 11, 2024 - "No vaccine-related serious adverse events were reported. Heterologous SCB-2019 boosting was well tolerated and elicited neutralizing responses against all tested SARS-COV-2 viruses including Omicron BA.1, BA.2, BA.4, BA.5, BF.7, BQ.1.1.3, and XBB1.5 sub-lineages that were non-inferior to homologous boosting with CoronaVac or Vaxzevria, but not homologous Comirnaty booster."
Journal • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases
|
|
Branda Hu; Camilo C Roa; Donna Ambrosino; Eric Plennevaux; Faith Gao; George Siber; Hannalyn Ilagan; Htay Htay Han; Igor Smolenov; Mari Rose A de Los Reyes; Ralf Clemens
|